Overview
Larry focuses on patent and trade secret matters before US district courts, the International Trade Commission (ITC), various arbitration panels, and the US Court of Appeals for the Federal Circuit. He has also handled numerous matters before the Patent Trial and Appeal Board (PTAB), representing predominantly biopharma clients in inter partes reviews. His PTAB experience spans from small molecule pharmaceutical patents to complex biologics patents. He has secured a number of favorable written decisions and strategic settlements, often leveraging a coordinated district court litigation strategy. His well-recognized oral and written advocacy skills, combined with his deep technical background, bolster his ability to present complex information in persuasive arguments before the Board.
In district courts, Larry has handled a wide range of technologies, including source code & software-defined radios, medical devices, chemical manufacturing (semiconductors, resins, polymers), architectural lighting, flat panel displays, printers, and fiber-optic telecommunications equipment.
Larry also has served as lead counsel in a highly publicized ITC investigation concerning misappropriation of chemical-related trade secrets, obtaining a 10-year exclusion order. He successfully defended that order on appeal to the Federal Circuit while working with customs officials to enforce the order.
Larry has also served as lead or primary IP counsel in a number of high-stakes life sciences pre-litigation assessments and litigations, including those involving proton pump inhibitors, cancer-related immunotherapies, tyrosine kinase inhibitors, thrombopoietin receptor agonists, and antibiotics.
Apart from litigation, Larry has served as lead IP counsel in various high-value transactions, including a $4.8 billion senior secured credit facility for a major Spanish pharmaceutical firm; the $1.5 billion acquisition of a diagnostics division of a multinational pharmaceutical company; the $4.4 billion acquisition of a prescription drug benefit management company; and numerous energy project finance deals, including several $1 to $2 billion solar and wind energy projects. Larry also has extensive experience in evaluating IP portfolios and preparing opinions of counsel; negotiating IP licenses, settlements, and transactional provisions; and performing IP due diligence.
Aside from private practice, Larry served as a Federal Circuit law clerk for the Honorable Alvin A. Schall. Prior to his legal career, he worked as a research scientist and development engineer concerning processes for efficient refining, cleaner fuels, and lower automobile emissions, for which he has received several patents.
- New York
- US Supreme Court
- US Court of Appeals, Federal Circuit
- US District Court, Southern District of New York
- US District Court, Eastern District of New York
- US Patent & Trademark Office
- Hon. Alvin A. Schall, US Court of Appeals, Federal Circuit
- J.D., Pace University
- B.S., State University of New York, Geneseo, Chemistry, cum laude
- B.S., State University of New York, Buffalo, Chemical Engineering, cum laude
Areas of Work
Speaking Engagements
-
"PTAB 2024 Year in Review," PTAB Bar Association, Webinar, February 26, 2025
- "Biologics Post-Grant Proceedings: Over a Decade of Experience," Intellectual Property Owners Association, Pharmaceutical and Biotechnology Issues Committee and U.S. Post-Grant Patent Office Practice Committee, August 3, 2023
- "It's Evidence, Not Argument! Incorporate Neither by Reference, PTAB Says in Parus Holdings v. Google," Intellectual Property Owners Association, US Post-Grant Office Practice Committee, June 13, 2023
- "Xerox Corp. v. Bytemark, Inc., and the Support Required for Expert Declarations in PTAB Litigation," Intellectual Property Owners Association, US Post-Grant Office Practice Committee, May 16, 2023
News & Publications
Publications
Director Vidal Addresses Serial IPR Petitions
PTAB Bar Association Appellate Year in Review 2024
January 2025
Publications
Inherency and Expectation: Federal Circuit Charts New Path in Obviousness Analysis
PTAB Bar Association Appellate Year in Review 2024
January 2025
By: Lawrence Kass
Publications
Fed. Circ. Inherency Ruling Refines Obviousness Framework
Law360
January 29, 2025
By: Lawrence Kass
Noteworthy
Awards
- Super Lawyers, New York, Intellectual Property Litigation (2019-2023)
- Managing Intellectual Property, IP Star (2015-2016)
- Intellectual Asset Magazine, Leading Patent Litigator (2014-2016)
- Federal Circuit Bar Association, George Hutchinson Award (2012)
Prior Publications
- "PTAB Reveals Route to IPR Institution Denial in Parallel Cases," Law360, March 18, 2021
- "'Teva' and Standard of Review on Patent Claim Construction," New York Law Journal, January 30, 2015
- “Therasense—Vaccine for a Plague," National Law Journal, June 6, 2011
- "Considering The Impact of New Legislation on Biologics in the US," Financier Worldwide, December 2010
- "The Challenger Is Prepared, Are You? Strategies for Preparing to Enforce Patents Covering Pharmaceutical Products," BNA's Patent, Trademark & Copyright Journal, 81 PTCJ 36, November 5, 2010
- "Implications of 'Ariad' for Describing Biological and Chemical Inventions," New York Law Journal, June 1, 2010
- "ITC Patent Dispute Over Wind Turbines Turns Political," National Law Journal, January 25, 2010
- "Is There a Written Description Requirement After All?," Law360, December 11, 2009
- "Abbott Laboratories v. Sandoz Inc.: Patenting a Product by Defining How It’s Made," BNA's Patent, Trademark & Copyright Journal, 79 PTCJ 86, November 20, 2009
- "Emerging Issues for Clean Energy Technologies," North American Clean Energy, August 2009
- "International Patent Prosecution After 'In re Bilski': Incorporating Limitations," New York Law Journal, December 2, 2008
- "Patent Exhaustion, Litigation, Licensing After 'Quanta'," New York Law Journal, August 6, 2008
- "Utility Must Be Specific, Practical," National Law Journal, October 17, 2005
- "FTC Takes Drug-Patent 'Reverse Payments' to High Court," New York Law Journal, October 3, 2005
- "Drug Patents in the Spotlight," New York Law Journal, February 28, 2003
- "Federal Circuit Reconsiders Ruling in 'Enzo Biochem'; Court Takes More Flexible View of the Written-Description Requirement," National Law Journal, October 14, 2002
- “More Flexible View of the Written-Description Requirement,” October 14, 2002
- "A Roadmap for Biotechnology Patents? Federal Circuit Precedent and the PTO's New Examination Guidelines," AIPLA Quarterly Journal, Spring 2002
- "Declaratory Judgements in Patent Cases," New York Law Journal, July 9, 2001
- "Business Method Initiatives," National Law Journal, May 7, 2001
- "A Computerized Business Method Is Patentable Subject Matter," New York Law Journal, August 6, 1998
Professional Affiliations
- Federal Circuit Bar Association
- PTAB and TTAB Committee
- Intellectual Property Owners (IPO) Association
- US Post-Grant Office Practice Committee
- PTAB Bar Association